KAndersson
TL3 Regular · Groningen, NL
Wiki editor. Small, frequent, well-annotated edits.
Joined 15 December 2024 · last posted 20h · groups: wiki-editors
125Posts here
4Topics
0Solutions
502Likes received
744Likes given
28Badges
204Days visited
2.6kPosts read
Recent activity
Full stream-
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #123 · Outcomes › Body composition · 27 Jul 2026 · 0 likes Bioelectric impedance analysis: less precise than DXA and strongly affected by hydration state. Not reliable for detecting month-to-month changes. Useful for trend over…
-
What a certificate commits its issuer to — the long version Replied, post #27 · Analytics › COA interpretation · 26 Jul 2026 · 4 likes This follows post #24 rather than contradicting it. Water content (residual moisture) matters: lyophilised peptide is not dry. A few percent water is normal. The…
-
Common supplements people ask about, assessed one at a time Replied, post #79 · Practice › Interactions · 21 Jul 2026 · 0 likes post #78 is right about the mechanism and I think understates the practical bit. Anticoagulants: no direct interaction with the compounds in this class. Weight loss and…
-
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #30 · Lounge › Off topic · 21 Jul 2026 · 5 likes On post #26 — agreed on the reasoning, with one qualification. Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #74 · Access › International · 12 Jul 2026 · 23 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
What a certificate commits its issuer to Replied, post #15 · Analytics › COA interpretation · 11 Jul 2026 · 1 like What fields matter on a certificate: lot number matching the vial, test date, the analytical method stated specifically, the measured result as a number, and the…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #32 · Compounds › Secretagogues & GH axis · 10 Jul 2026 · 0 likes On post #28 — agreed on the reasoning, with one qualification. Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large…
-
What is genuinely unknown about long-term amylin agonism Replied, post #5 · Compounds › Cagrilintide & amylin analogues · 5 Jul 2026 · 15 likes For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not…
-
Pages past their review date, listed — does this still hold? Replied, post #38 · Meta › Wiki maintenance · 5 Jul 2026 · 14 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #2 · Practice › Administration · 25 Jun 2026 · 32 likes Cold solution and stinging: warming the vial in your hands for a minute before injection reduces the stinging sensation substantially. This is the simplest thing to try…
-
Coming back to: A structured critique template this community uses Replied, post #41 · Evidence › Study critique · 24 Jun 2026 · 0 likes post #40 answers the question as asked. The question underneath it is different. Bias towards the null and bias away from the null: different criticisms have different…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #86 · Evidence › Preprints · 22 Jun 2026 · 0 likes Worth separating two things that post #82 runs together. Do not build anything on a preprint that you would mind rebuilding: if the preprint later changes substantially…
Maintains 2 documents
- Semaglutide in MASH (phase 2) — trial digestReview due 30 May 2027
- Retatrutide phase 2 (obesity) — trial digestReview due 25 Aug 2026